Breath biomarkers could lead to non-invasive detection and monitoring for liver disease, diabetes, kidney disease, heart failure and other cardiometabolic diseases.
)

Cardiovascular & Metabolic Diseases

Breath biomarkers could lead to non-invasive detection and monitoring for liver disease, diabetes, kidney disease, heart failure and other cardiovascular and metabolic diseases

Find out more
Webinar
)

Webinar: Identifying Translational Biomarkers using Breath Biopsy in vitro Headspace Analysis

A webinar introducing in vitro methods to investigate volatile metabolites as potential translational biomarkers

View Presentation
Non-invasive breath testing offers an attractive alternative to currently available diabetes tests for diagnosis and ongoing monitoring
)

Article: Insights into potential VOC biomarkers of diabetes

Non-invasive breath testing offers an attractive alternative to currently available diabetes tests for diagnosis and ongoing monitoring

Read Review
A non-invasive breath test could allow for cheaper screening and earlier intervention, when damage is less severe
)

Article: Examining candidate breath biomarkers for kidney disease

A non-invasive breath test could allow for cheaper screening and earlier intervention, when damage is less severe

View Publication
Current biomarkers of cardiovascular disease and heart function are accessed invasively and burdensome for the patient. Breath biomarkers could be of huge value.
)

Case Study: Could acetone be a biomarker of heart failure?

Current biomarkers of heart function are very invasive but evidence suggests breath acetone could be useful for both diagnosis and prognosis

Read Case study
Publication
)

Paper: Breath Biopsy to identify exhaled VOCs as biomarkers for liver cirrhosis

A study to discover VOCs for early detection of progressive liver disease

VIEW PAPER

In developed countries, driven by poor diet and low exercise, fatty liver diseases have quietly reached epidemic levels across both adults and children. In the early stages, symptoms of liver disease are few, which is why the scale of the problem has gone largely unnoticed. With care the liver can heal itself, but without timely action liver damage can become permanent.

The economic impact of liver disease is enormous. For example, in the United States approximately 30% of US adults and as many as 1 in 10 children suffer from some form of liver disease, leading to direct and societal costs estimated at almost $300B per year. There is therefore an acute need for earlier detection when lifestyle changes and therapeutics can be effectively deployed, and the number of patients experiencing severe symptoms reduced.

Case Studies

A detailed look at some of the research studies investigating biomarkers for cardiovascular and metabolic diseases.

We’ve worked on cardiovascular and metabolic disease with these groups:

University of Birmingham logo Cancer Research UK Logo Cleveland Clinic News
A graphic showing the latest BB statistics.

See our latest progress.

Read more about Breath Biopsy.